MaaT Pharma Challenges Negative EMA Opinion on Graft-Versus-Host Disease Therapy
Event summary
- MaaT Pharma plans to request a re-examination of the negative CHMP opinion on MaaT013 (Xervyteg®) for treating acute Graft-versus-Host Disease (aGvHD).
- The CHMP cited concerns over the attribution of clinical effects due to concomitant therapies in the ARES study.
- A new CHMP opinion is expected by September 2026 following the re-examination request.
- MaaT Pharma will seek input from hematology experts via a Scientific Advisory Group (SAG) hearing.
The big picture
MaaT Pharma’s push for re-examination reflects the broader challenge biotech firms face in proving the efficacy of novel therapies amidst complex patient treatment regimens. The outcome could set a precedent for microbiome-based treatments in oncology, particularly where standard therapies fall short.
What we're watching
- Regulatory Strategy
- Whether MaaT Pharma can successfully argue the clinical efficacy of MaaT013 despite the CHMP's concerns over concomitant therapies.
- Clinical Validation
- The impact of real-world evidence from the Early Access Program on future regulatory decisions.
- Pipeline Diversification
- How MaaT Pharma's development of MaaT033 and MaaT034 will influence investor confidence amid regulatory setbacks.
Related topics